Lipid Lowering Flashcards

(38 cards)

1
Q

What two statins are prodrugs?

A

lovastatin

simvastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Effect of omega-3 fatty acid supplements on blood lipids

A

decrease TG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Effect of statins on blood lipids

A

reduce LDL

modest reduction in TG and increase in HDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

higher intensity lipid lowering statin

A

atorvastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

metabolized by CYP3A4

A

atorvastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

metabolized by sulfating (NOT p450 dependent)

A

pravastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

except atorvastatin, statins are administered ______ (time of day), when cholesterol biosynthesis takes place

A

QHS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

half life:
atorvastatin _______ hrs
pravastatin ________ hrs

A
14 h (take any time)
2 h (take QHS)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

statin that is excreted unchanged in urine

A

pravastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

statin that is not protein bound

A

pravastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

effect of taking food with drug

A

decreased absorption of drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

statin that crosses BBB

A

atorvastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

well known adverse effect of atorvastatin, when combined with gemfibrozil (inhibits uptake) or drugs that inhibit CYP3A4 (TONS!)

A

myopathy/myalgia

rhabdomyolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

statin that is hydrophilic and hepatoselective

A

pravastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

cholesterol absorption blocker at brush border (inhibits Niemann-Pick C1-Like 1)

A

ezetimibe (and its glucuronirated metabolite)

increases expression of LDL-receptor (increased clearance)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

effect of ezetimibe on lipid levels

A

decrease LDL, especially as adjunct

combined with statin - no P450 involvement

17
Q

half life:

ezetimibe

A

22 hours

long due to enterohepatic circulation

18
Q

effect of cholestyramine on lipid levels

A

reduce LDL

modest increase in HDL and TG

19
Q

binds bile acids in the GI –> excretion

A

cholestyramine

up regulates LDL-receptor to increase conversion of cholesterol to bile

20
Q

contraindication to cholestyramine

21
Q

give this medication 1 hr after or 2 hrs before other drugs

A

cholestyramine

can bind and impair absorption of other drug

22
Q

effect of niacin on lipid levels

A

increases HDL

lowers TG and LDL

23
Q

inhibits lipolysis in adipose tissue for transport to liver (for VLDL synthesis)

A

niacin (vitamin B3) at high doses

24
Q

contraindications for niacin

A

pregnancy

caution with existing liver and GI issues

25
adverse effect of niacin
flushing (declines over 1-2 weeks) hepatotoxicity (heavy first pass metabolism) Dyspepsia (huge doses!)
26
effect of fibrates on lipid levels
lower TG
27
only fibrate shown to impact outcomes:
gemfibrozil
28
gemfibrozil MOA
agonist for PPAR-alpha receptor (transcription factor) essentially - decreases TG synthesis and increases clearance
29
half life gemfibrozil
1.1 hours
30
adverse effects of gemfibrozil
myopathy GI discomfort DRUG interactions due to inhibition of transporter (warfarin, OCP)
31
contraindications for gemfibrozil
pregnancy | children
32
best drug for increasing HDL
niacin
33
best drug for lowering LDL
statins
34
best drug for lowering TG
fibrates, niacin, omega-3 | only gemfibrozil clinically significant
35
What does PCSK9 do?
binds to LDL-R leading to its degradation
36
evolocumab (Repatha)
PCSK9 inhibitors
37
problems with evolocumab
injected only expensive nasopharyngitis ?seem not too efficacious?
38
indication for evolocumab (who gets it?)
familial homozygous hypercholesterolemia